Cardiovascular Drugs and Therapy最新文献

{"title":"Aspirin Instead of Clopidogrel after Percutaneous Coronary Intervention in Atrial Fibrillation: More than just an Option.","authors":"Andrea Rubboli, Riccardo Panevino, Graziella Pompei","doi":"10.1007/s10557-026-07894-3","DOIUrl":"10.1007/s10557-026-07894-3","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"2101-2103"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148013840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reflections on Oral Beta Blocker Therapy and Long-term Outcomes after Myocardial Infarction in Preserved Left Ventricular Function.","authors":"Reza Yaghoubi Nezhad, Hossein Zare, Ali Abasi","doi":"10.1007/s10557-026-07880-9","DOIUrl":"10.1007/s10557-026-07880-9","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"2099-2100"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147986713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sources of Heterogeneity in the Efficacy of Statins for Primary Prevention of Cardiovascular Diseases: A Systematic Review with Meta-Regression and Meta-Analysis of Within-Study Subgroup Differences.","authors":"Yujun Long, Jianzhao Liu, Jiaxin Cai, Qiongqi Zhuang, Ting Cai, Junwen Zhou, Sanbao Chai, Tengfei Lin, Zhirong Yang","doi":"10.1007/s10557-026-07883-6","DOIUrl":"10.1007/s10557-026-07883-6","url":null,"abstract":"<p><strong>Purpose: </strong>Evidence regarding sources of heterogeneity in the efficacy of statins for primary prevention of cardiovascular disease (CVD) remains limited. This study aimed to identify trial-level factors contributing to such heterogeneity.</p><p><strong>Methods: </strong>Relevant studies were systematically identified from a previous systematic review and through searches in PubMed, Embase, and Cochrane up to 20 January 2026. The protocol was registered in PROSPERO (CRD42024579932). Randomized controlled trials (RCTs) in adults without prior CVD that investigated statin treatment were included. Risk of bias was assessed using the Cochrane Risk of Bias tool. Meta-analyses were conducted to pool risk ratios (RRs) and 95% confidence intervals (CIs) for major adverse cardiovascular events (MACE), myocardial infarction (MI), stroke, and cardiovascular death. Univariate meta-regression analyses were conducted to assess the impact of trial-level covariates on the effect sizes, expressed as the ratio of risk ratios (RRR). Within-study subgroup differences were meta-analyzed by pooling ratio of effect sizes. Meta-regression analyses were conducted using complete-case trial-level data.</p><p><strong>Results: </strong>25 RCTs (102,667 participants) were included. Compared to no statin treatment, statin treatment was associated with a reduced risk of MACE (RR, 0.73[95% CI, 0.67 to 0.80], P < 0.001), MI (RR, 0.68[95% CI, 0.60 to 0.77], P < 0.001), stroke (RR, 0.76[95% CI, 0.65 to 0.89], P = 0.001) and cardiovascular death (RR, 0.81[95% CI, 0.71 to 0.95], P = 0.008). Univariate meta-regression indicated that higher baseline total cholesterol (RRR, 1.29 [95% CI, 1.07 to 1.57], P = 0.008), higher low-density lipoprotein cholesterol (LDL-C) (RRR, 1.31 [95% CI, 1.07 to 1.62], P = 0.010), higher triglycerides (RRR, 1.81 [95% CI, 1.17 to 2.81], P = 0.008) and lower statin intensity (RRR, 0.74 [95% CI, 0.59 to 0.94], P = 0.015) were significantly associated with reduced efficacy of statins for stroke prevention at the trial level.</p><p><strong>Conclusions: </strong>Statin therapy demonstrated consistent efficacy in CVD prevention across diverse populations, except that baseline lipid profiles and statin intensity may represent exploratory, hypothesis-generating signals of potential effect modification for stroke prevention, warranting further investigation.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"2049-2060"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardioprotection with Intralipid during CABG.","authors":"Ataollah Eskandari, Saeed Taghavi, Ali Hosseini","doi":"10.1007/s10557-026-07854-x","DOIUrl":"10.1007/s10557-026-07854-x","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"2083-2084"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146156110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dexmedetomidine Attenuates Myocardial Ischemia/Reperfusion Injury by Inhibiting DNMT3B-Mediated Hypermethylation of the KLF4 Promoter.","authors":"XinJing Chen, Jingxuan Hong","doi":"10.1007/s10557-026-07869-4","DOIUrl":"10.1007/s10557-026-07869-4","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"1705-1727"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hexosamine Biosynthetic Pathway and Fatty Acid β-Oxidative Imbalance: A Key Mechanism by Which Abnormal Macrophage Lipophagy Promotes Atherosclerosis in Diabetes.","authors":"Jin-Ping Liu, Yu-Hui Liu, Hao Luo, Yi-Fei Wu, Shuai-Yi Yu, Ya Wu, Yong Liu","doi":"10.1007/s10557-026-07876-5","DOIUrl":"10.1007/s10557-026-07876-5","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"1941-1963"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147670521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Success Rates, Complications, and Mortality with Laser Lead Extraction of Cardiovascular Implantable Electronic Devices.","authors":"Patrick T Lynch, Emily Y Xiao, Faiz M Baqai, Derrick A Draeger, Alexandra M Lewis, Mehdi Razavi, Nilesh Mathuria, Jie Cheng, John Seger, Abdi Rasekh, Mohammad Saeed, Mihail G Chelu","doi":"10.1007/s10557-026-07868-5","DOIUrl":"10.1007/s10557-026-07868-5","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"1771-1779"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147490730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vps16 Attenuates Myocardial Ischemia/reperfusion Injury by Interacting with UVRAG and Activating Rab7.","authors":"Yuanbin Li, Jinhao Zhou, Dan Wang, Xu Yan, Yiguo Ouyang, Wei Wang, Chenyao Zhu, Zhuang Chen","doi":"10.1007/s10557-026-07865-8","DOIUrl":"10.1007/s10557-026-07865-8","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"1685-1704"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ANRIL in Cardiovascular Diseases: Expression, Mechanism and Therapeutic Implications.","authors":"Hao Yang, Ying Li, Qiushuang Cai, Huimin Hua, Xia Liu, Yifei Liu, Wei Qin, Renfang Mao","doi":"10.1007/s10557-026-07884-5","DOIUrl":"10.1007/s10557-026-07884-5","url":null,"abstract":"<p><p>Cardiovascular diseases (CVDs) remain a leading cause of global mortality, with pathogenesis driven by multifactorial processes including genetic susceptibility, metabolic dysregulation, angiogenesis, and inflammation. Long non-coding RNAs (lncRNAs) have been recognized as key modulators of gene expression in cardiovascular pathophysiology. Among them, the Antisense Non-coding RNA in the INK4 Locus (ANRIL)-mapping to the well-established CVD-associated chromosome 9p21 locus-has garnered substantial research interest. Initially identified in melanoma, ANRIL spans approximately 126.3 kb and comprises 19 exons, existing in both linear and circular isoforms with distinct functional profiles. This review systematically outlines the dysregulation of ANRIL expression across seven major cardiovascular conditions and elucidates the isoform-specific mechanisms through which it contributes to disease progression, integrating recent advances in this field. We further discuss emerging evidence suggesting a potential role of ANRIL in cardiac hypertrophy. In light of its involvement in diverse cardiovascular disorders, ANRIL represents a compelling candidate for therapeutic target and a promising biomarker, warranting further translational investigation.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"2029-2048"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baxdrostat and Aldosterone Synthase Inhibitors: A New Class for Treatment-resistant Hypertension.","authors":"Ahmar Jan Qureshi, Muhammad Riyyan Tariq Tagga, Abdul Qayum Khan","doi":"10.1007/s10557-026-07887-2","DOIUrl":"10.1007/s10557-026-07887-2","url":null,"abstract":"<p><strong>Purpose: </strong>To review the mechanistic rationale and recent Phase 3 clinical trial data for baxdrostat, a selective aldosterone synthase inhibitor, in the management of treatment-resistant hypertension.</p><p><strong>Methods: </strong>We evaluated efficacy and safety data from the Phase 3 BaxHTN (N = 794) and Bax24 (N = 217) trials, along with a recent systematic review and meta-analysis of aldosterone synthase inhibitors.</p><p><strong>Results: </strong>In BaxHTN, baxdrostat 2 mg reduced seated systolic blood pressure by -15.7 mmHg (placebo-adjusted - 9.8 mmHg; P < 0.001). In Bax24, 24-hour ambulatory systolic blood pressure decreased by -16.6 mmHg (placebo-adjusted - 14.0 mmHg; P < 0.001). Hyperkalemia (> 5.5 mmol/L) occurred in approximately 12% of baxdrostat-treated patients versus 3% with placebo, with low discontinuation rates (approximately 2%). No cortisol suppression or adrenal insufficiency was observed.</p><p><strong>Conclusion: </strong>Baxdrostat has demonstrated among the largest ambulatory blood pressure reductions reported in contemporary treatment-resistant hypertension trials. With FDA Priority Review underway (PDUFA Q2 2026), this first-in-class agent represents a potential therapeutic advancement for patients inadequately controlled on existing regimens.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"2091-2093"},"PeriodicalIF":3.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147926695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}